NCT05223699View on ClinicalTrials.gov

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Acute Myeloid LeukemiaMyelodysplasia
Interventions
BIOLOGICAL

MGTA-117

MGTA-117 will be administered as an IV infusion

Trial Locations (8)

14203

Roswell Park Comprehensive Cancer Center, Buffalo

33612

Moffitt Cancer Center, Tampa

55455

University of Minnesota, Minneapolis

63110

Washington University School of Medicine, St Louis

66205

The University of Kansas Cancer Center, Westwood

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthONE, Denver

91010

City of Hope, Duarte

Sponsors
All Listed Sponsors
lead

Magenta Therapeutics, Inc.

INDUSTRY